HRP20220759T1 - Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti - Google Patents

Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti Download PDF

Info

Publication number
HRP20220759T1
HRP20220759T1 HRP20220759TT HRP20220759T HRP20220759T1 HR P20220759 T1 HRP20220759 T1 HR P20220759T1 HR P20220759T T HRP20220759T T HR P20220759TT HR P20220759 T HRP20220759 T HR P20220759T HR P20220759 T1 HRP20220759 T1 HR P20220759T1
Authority
HR
Croatia
Prior art keywords
image
compound
preparation
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
HRP20220759TT
Other languages
English (en)
Inventor
Daniel DE ROULET
Robert Devita
Original Assignee
Mitokinin, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokinin, Inc. filed Critical Mitokinin, Inc.
Publication of HRP20220759T1 publication Critical patent/HRP20220759T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (11)

1. Spoj odabran iz skupine koju čine: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] i [image] ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1, naznačen time što je spoj odabran između: [image] [image] [image] i [image]
3. Spoj prema zahtjevu 1, naznačen time što je spoj odabran između: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image]
4. Pripravak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 3.
5. Pripravak koji sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1 do 3 i jedno drugo aktivno sredstvo.
6. Farmaceutski pripravak koji sadrži spoj, pripravak, ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1-5.
7. Spoj prema zahtjevu 1 do 3, ili pripravak prema zahtjevu 4 ili 5, ili farmaceutski pripravak prema zahtjevu 6, za uporabu u postupku liječenja i/ili prevencije neurodegenerativne bolesti kod subjekta.
8. Spoj, pripravak ili farmaceutski pripravak za uporabu prema zahtjevu 7, naznačen time što je neurodegenerativna bolest Huntingtonova bolest ili Parkinsonova bolest.
9. Spoj prema zahtjevima 1 do 3, ili pripravak prema zahtjevu 4 ili 5, ili farmaceutski pripravak prema zahtjevu 6, za uporabu u postupku liječenja i/ili prevencije mitohondrijske bolesti kod subjekta.
10. Spoj, pripravak ili farmaceutski pripravak za uporabu prema zahtjevu 9, naznačen time što je mitohondrijska bolest kardiomiopatija.
11. Komplet koji sadrži barem prvi spremnik koji sadrži terapeutski učinkovitu količinu jednog ili više spojeva, ili njihovu farmaceutski prihvatljivu sol, prema zahtjevima 1 do 3 ili pripravak prema zahtjevu 4 ili 5, ili farmaceutski pripravak koji sadrži terapeutski učinkovitu količinu jednog ili više spojeva, ili njihova farmaceutski prihvatljiva sol, prema zahtjevu 6; i, izborno, barem drugi spremnik s otopinom za resuspenziju.
HRP20220759TT 2014-02-11 2015-02-11 Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti HRP20220759T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461938691P 2014-02-11 2014-02-11
PCT/US2015/015513 WO2015123365A1 (en) 2014-02-11 2015-02-11 Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP15748579.8A EP3104706B1 (en) 2014-02-11 2015-02-11 Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease

Publications (1)

Publication Number Publication Date
HRP20220759T1 true HRP20220759T1 (hr) 2022-09-02

Family

ID=53800607

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220759TT HRP20220759T1 (hr) 2014-02-11 2015-02-11 Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti

Country Status (7)

Country Link
US (3) US10167286B2 (hr)
EP (1) EP3104706B1 (hr)
AU (5) AU2015217152A1 (hr)
CA (1) CA2939219C (hr)
ES (1) ES2919024T3 (hr)
HR (1) HRP20220759T1 (hr)
WO (1) WO2015123365A1 (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939219C (en) 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
LT3237418T (lt) 2014-12-23 2019-05-10 Novartis Ag Triazolpirimidino junginiai ir jų panaudojimas
DK3244891T3 (da) 2015-01-16 2022-10-24 Massachusetts Gen Hospital Forbindelser til forbedring af mrna-splejsning
CN106986874B (zh) * 2016-01-20 2019-09-24 西华大学 (1H-吡唑[3,4-d]嘧啶)-4-氨基衍生物及其作为IDO抑制剂在药物制备中的用途
WO2017133258A1 (zh) * 2016-02-04 2017-08-10 西华大学 1h-吲唑类衍生物及其作为ido抑制剂的用途
CN107840826B (zh) * 2016-09-19 2021-07-09 西华大学 1h-吲唑类衍生物及其作为ido抑制剂的用途
BR112018076443A2 (pt) 2016-06-20 2019-04-09 Novartis Ag formas cristalinas de um composto de triazolopirimidina
JP2019522049A (ja) 2016-06-20 2019-08-08 ノバルティス アーゲー トリアゾロピリジン化合物及びその使用
EP3472166A1 (en) 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidine compounds useful for the treatment of cancer
WO2018237145A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
AU2020253561A1 (en) * 2019-04-03 2021-12-02 Mitokinin, Inc. Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
US20220389067A1 (en) * 2019-11-05 2022-12-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treating Neurodegenerative Diseases Caused by G4C2 Expansion in C9ORF72
CZ310035B6 (cs) * 2019-12-09 2024-05-29 Univerzita PalackĂ©ho v Olomouci N-(furan-2-ylmethyl)-7H-purin-6-amin pro modulaci cirkadiánních rytmů
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
EP4267192A1 (en) * 2020-12-22 2023-11-01 The Trustees of Columbia University in the City of New York Compositions and methods for treating patients with mitochondrial complex i deficiency using caspase-9 signaling pathway inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
SE352811B (hr) 1971-06-04 1973-01-15 Pharmacia Ab
US3960150A (en) 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3867519A (en) 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
SE375007B (hr) 1972-11-30 1975-04-07 Pharmacia Ab
US3963025A (en) 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
JPS5825980B2 (ja) 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US5401629A (en) 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9311132D0 (en) 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
PE91698A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
ATE307111T1 (de) 1999-01-13 2005-11-15 Genentech Inc Serinprotease-inhibitoren
CA2394646A1 (en) * 1999-12-17 2001-06-21 Ariad Pharmaceuticals, Inc. Novel purines
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN1173043C (zh) * 2001-04-14 2004-10-27 赵天增 一种合成β－二氢沉香呋喃倍半萜多醇酯类化合物的方法
US20090247557A1 (en) 2001-07-13 2009-10-01 Arvinder Dhalla Partial and full agonists of a1 adenosine receptors
US20070161582A1 (en) 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
ES2432113T3 (es) 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
JP5048520B2 (ja) 2005-02-04 2012-10-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素の阻害剤
US9265724B2 (en) 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
US20070270362A1 (en) 2006-05-18 2007-11-22 The University Of Washington Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
CN100493510C (zh) 2007-06-04 2009-06-03 西北农林科技大学 6-糠氨基嘌呤用于制备治疗心肌组织氧化损伤药物的应用
CN100493506C (zh) 2007-06-04 2009-06-03 西北农林科技大学 化合物6-糠基氨基嘌呤在制备抗脑组织氧化损伤药物应用
US7960397B2 (en) 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
GB0819530D0 (en) 2008-10-24 2008-12-03 Univ Sheffield Methods and compositions
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
KR20120079054A (ko) 2009-07-10 2012-07-11 에볼바 아게 디인 조성물
WO2011069294A1 (zh) 2009-12-10 2011-06-16 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
CA2790682C (en) 2010-03-03 2020-11-24 Neocutis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
DE102010040615A1 (de) * 2010-09-13 2012-03-15 Siemens Aktiengesellschaft Teilchenbeschleuniger mit in die Beschleunigerzelle integriertem Spannungsvervielfacher
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
CA2837207A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2013052699A2 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
CN102727499A (zh) 2012-06-29 2012-10-17 西北农林科技大学 化合物6-糠基氨基嘌呤在制备抗血管性痴呆药物的应用
EP2953950B1 (en) 2013-02-11 2021-01-13 The Regents of The University of California Compositions and methods for treating neurodegenerative diseases
NZ750581A (en) 2013-02-11 2020-08-28 Univ California Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
CA2939219C (en) 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2018237145A1 (en) * 2017-06-21 2018-12-27 Mitokinin, Inc. COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
WO2020116061A1 (ja) 2018-12-07 2020-06-11 パナソニック株式会社 ランキンサイクル装置およびその制御方法

Also Published As

Publication number Publication date
EP3104706A4 (en) 2017-08-02
US10167286B2 (en) 2019-01-01
AU2019202922A1 (en) 2019-05-23
US20210107910A1 (en) 2021-04-15
US10851109B2 (en) 2020-12-01
CA2939219A1 (en) 2015-08-20
ES2919024T3 (es) 2022-07-21
AU2015217152A1 (en) 2016-08-11
US20220274989A9 (en) 2022-09-01
US20190194207A1 (en) 2019-06-27
EP3104706A1 (en) 2016-12-21
WO2015123365A1 (en) 2015-08-20
AU2022203221A1 (en) 2022-06-02
AU2019202922B2 (en) 2020-12-03
AU2024200901A1 (en) 2024-02-29
US20170190704A1 (en) 2017-07-06
EP3104706B1 (en) 2022-03-23
AU2020264342A1 (en) 2020-12-03
CA2939219C (en) 2023-02-28

Similar Documents

Publication Publication Date Title
HRP20220759T1 (hr) Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
HRP20240218T1 (hr) Modulatori integriranog puta stresa
HRP20210529T1 (hr) Inhibitori za mk2 i njihove uporabe
HRP20180591T1 (hr) Inhibitori kinaze serina ili treonina
HRP20221158T1 (hr) Sredstva za izazivanje apoptoze
HRP20230274T1 (hr) Kemijski spojevi
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
HRP20230222T1 (hr) Modulatori prolijekova integriranog puta stresa
HRP20212014T1 (hr) Spoj peptida
JP2013014622A5 (hr)
JP2014507446A5 (hr)
CL2016001424A1 (es) Composiciones de liberación retardada de lionaclotida
HRP20230584T1 (hr) Prolijekovi gemcitabina
JP2014218522A5 (hr)
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
HK1255313A1 (zh) 含有培美曲塞或其藥學上可接受的鹽的穩定藥物組合物
PL3315117T3 (pl) Kompozycja do higieny jamy ustnej dostarczająca środki aktywne do pielęgnacji jamy ustnej
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EP3569242A4 (en) PHARMACEUTICAL COMPOSITION WITH SULGLYCOTIDE OR PHARMACEUTICALLY SAFE SALT THEREOF FOR THE PREVENTION OR TREATMENT OF DRY EYES
PT3236938T (pt) Composições farmacêuticas aquosas tópicas orais de flurbiprofeno e dexpantenol
WO2016020408A3 (en) Compounds for preventing ototoxicity